Introduction
============

Lung cancer is the leading cause of cancer-associated mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for \~85% of all lung cancer cases ([@b1-ol-0-0-6607]). The prognosis for patients with NSCLC remains poor, with a 5-year survival rate of \~17% ([@b2-ol-0-0-6607]). The low survival rate of NSCLC is primarily due to tumor cell metastasis ([@b3-ol-0-0-6607]). Therefore, it is necessary to investigate the mechanisms underlying NSCLC metastasis.

MicroRNAs (miRNAs) are 19--24 nucleotides small non-coding RNAs, which directly bind to target motifs in mRNAs and post-transcriptionally suppress gene expression by transcript degradation or translational repression ([@b4-ol-0-0-6607],[@b5-ol-0-0-6607]). There is growing evidence that miRNA dysfunction is involved in the growth and/or metastasis of various types of human tumors ([@b6-ol-0-0-6607],[@b7-ol-0-0-6607]). MicroRNA (miR)-124, a widely studied miRNA, was demonstrated to be downregulated and regarded as a tumor suppressor in breast, gastric and bladder cancer, as well as head and neck squamous cell carcinoma ([@b8-ol-0-0-6607]--[@b11-ol-0-0-6607]). Xi *et al* ([@b12-ol-0-0-6607]) and Sun *et al* ([@b13-ol-0-0-6607]) recently demonstrated that miR-124 significantly repressed cell invasion and metastasis in colorectal cancer and NSCLC. Decreased expression of miR-124 was associated with poor prognosis in patients with breast cancer or NSCLC ([@b14-ol-0-0-6607],[@b15-ol-0-0-6607]). These results suggested that miR-124 may serve an important role in the regulation of tumor metastasis. Although miR-124 may inhibit NSCLC metastasis by targeting MYO10 ([@b13-ol-0-0-6607]), the other targets of miR-124 in this process cannot be excluded.

LIM-homeobox domain 2 (LHX2), a member of the LIM-homeodomain proteins, was previously reported to serve an important role in the control of lymphoid and neural cell differentiation and brain and eye development ([@b16-ol-0-0-6607]). LHX2 was also implicated in the development of various types of human tumors. For example, LHX2 may promote breast cancer cell growth and metastasis by stimulating the activity of platelet-derived growth factor subunit B signaling pathway ([@b17-ol-0-0-6607]). The authors of the present study previously demonstrated that LHX2 was highly expressed and may serve an oncogenic role in NSCLC ([@b18-ol-0-0-6607]). Although data of the previous study demonstrated that knockdown of LHX2 inhibited NSCLC cell proliferation and arrested cell cycle at G~1~ phase ([@b18-ol-0-0-6607]), it remains unclear whether LHX2 affects the migratory and invasive abilities of NSCLC cells.

Low miR-124and high LHX2 expression levels have been observed in different cancer types in humans. Therefore, there may be a link between miR-124 and LHX2 in NSCLC. In order to investigate this hypothesis, the present study first used TargetScanHuman v7.0 software to predict miRNA targets and demonstrated that the 3′-untranslated region (3′-UTR) of the LHX2 transcript was a putative target of miR-124. therefore, this attracted our attention to the association between miR-124 and LHX2 in NSCLC.

To the best of our knowledge, the present study is the first time that the role of LHX2 in NSCLC cell invasion and an association between miR-124 and LHX2 in NSCLC has been investigated. The results revealed that LHX2 has an important role in promoting NSCLC cell migration and invasion, which maybe controlled at least partially by miR-124.

Materials and methods
=====================

### Cell culture

Human bronchial epithelial (HBE) cells (Bogoo Biotechnology, Shanghai, China) and human NSCLC cells A549, LTEP-a2, H1299 (two lung adenocarcinoma cell lines), H226 (lung squamous carcinoma cell line), 95C and 95D (two giant-cell carcinoma cell lines) and H460 (large cell carcinoma cell line) from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), were cultured in RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), L-glutamine and 50 U/ml each of penicillin and streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C with 5% CO~2~ in a humidified atmosphere.

### Tissue samples

A total of 40 paired tumor tissues and adjacent noncancerous tissues were collected, by surgical resection, from patients with NSCLC at the First Affiliated Hospital of Soochow University (Suzhou, China) between April 2007 and December 2013. The demographic and clinical features were described in [Table II](#tII-ol-0-0-6607){ref-type="table"}. Written informed consent was obtained from all patients prior to enrollment in the present study. Histological and pathological diagnostics for patients with NSCLC were evaluated according to the Revised International System for Staging Lung Cancer ([@b19-ol-0-0-6607]). None of the patients received chemotherapy or radiotherapy prior to tissue sampling. The samples were snap-frozen in liquid nitrogen and stored at −80°C. The present study was approved by the Academic Advisory Board of Soochow University.

### RNA extraction, cDNA synthesis and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from NSCLC cells and human NSCLC tissues using the HP Total RNA kit (Omega Bio-Tek, Inc., Norcross, GA, USA). Purified RNA was reversed transcribed to cDNA using the M-MLV cDNA Reverse Transcription kit (Invitrogen; Thermo Fisher Scientific, Inc.), and the sequences of the primers used are presented in [Table I](#tI-ol-0-0-6607){ref-type="table"}. RT-PCR was performed using a Platinum SYBR Green qPCR SuperMix-UDG kit (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol on Roche Lightcycler 96 (Roche Diagnostics, Basel, Switzerland). The thermocycling conditions for qPCR were as follows: 95°C for 5 min, 40 cycles of 95°C for 10 sec, 60°C for 30 sec, followed by 72°C for 10 min. Each RT-qPCR experiment was performed in triplicate. The relative expression levels of LHX2 mRNA and miR-124 were normalized to β-actin mRNA and U6, respectively, and evaluated according to the 2^−ΔΔCt^ method ([@b20-ol-0-0-6607]).

### Western blot analysis

Cells and tissues were lysed and subjected to western blot analysis as previously described ([@b7-ol-0-0-6607]). Antibodies applied in the analysis were as follows: rabbit anti-LHX2 (catalog no. sc-367972; dilution, 1:1,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and mouse anti-β-actin (catalog no. CW0096M; dilution, 1:2,000; CWBIO, Beijing, China) primary antibodies, and horseradish peroxidase (HRP)-conjugated goat anti-rabbit (catalog no. CW0103S; dilution, 1:3,000; CWBIO) or HRP-conjugated goat anti-mouse secondary antibodies (catalog no. CW0107S; dilution, 1:3,000; CWBIO). The LHX2 expression level was normalized to β-actin.

### Plasmid construction and luciferase assay

A 72 base pair (bp) DNA sequence of LHX2 3′-UTR containing a predicted miR-124 target site (position 315--312, predicted using TargetScanHuman software; version 7.0; [www.targetscan.org](www.targetscan.org)) was directly synthesized (GENEWIZ, Suzhou, China) and subcloned into a dual-luciferase report vector, psiCHECK-2 (Promega Corporation, Madison, WI, USA), in order to generate a psiCHECK-2-LHX2 3′-UTR-wildtype. In addition, another similar 72 bp DNA fragment containing a mutant miR-124 target site was synthesized for construction of a psiCHECK-2-LHX2 3′UTR-mutant vector (GENEWIZ). Subsequently, each of the luciferase constructs was co-transfected with miR-124 mimics (5-UAA GGC ACG CGG UGA AUG CC-3′) or a scrambled negative control (miR-NC; 5′-UUCUCCGAACGUGUCACGUTT-3′) into A549 and H1299 cells, respectively. Following transfection for 48 h at 37°C, the cells were lysed and analyzed for luciferase activities using the dual-luciferase reporter assay system (Promega Corporation). Each experiment was performed in triplicate. Results are represented as relative to Renilla luciferase activities, which were normalized to firefly luciferase activities. All transient transfections, including anti-miR-124 (5′-GGCAUUCACCGCGUGCCUUA-3′) and anti-miR-NC (5′-CAGUACUUUUGUGUAGUACAA-3′) were performed using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s instructions.

### Transient RNA interference

Two short interfering RNAs (siRNA), which specifically target the LHX2 transcript were directly synthesized (GenePharma Co., Ltd., Shanghai, China). Sequences for LHX2 siRNAs were as follows: si-LHX2-1, 5′-GCTTCGGACCATGAAGTCTTA-3′; si-LHX2-2, 5′-GCAACCTCTTACGGCAGGAAA-3′. A scrambled sequence (5′-TTCTCCGAACGTGTCACGT-3′) was used as the negative control (si-NC). The cells were transiently transfected with 100 pmol of siRNA or si-NC for 48 h at 37°C, using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.). Following 3 days, the cells were collected for further experiments.

### Transwell migration and Matrigel invasion assays

Transwell migration and Matrigel invasion assays were performed using Transwell plates with 0.8 µm pore polycarbonate membranes (BD Biosciences, Franklin Lakes, NJ, USA). A549 and H1299 cells (5×10^4^) supplemented with 1% FBS were seeded in the upper chamber \[for the invasion assay, Matrigel (Corning, NY, USA) was added in the upper chamber prior to cell seeding\] and allowed to invade to the reverse side of the chamber under chemoattractant conditions with 10% FBS medium in the lower chamber. Following incubation for 48 h at 37°C, the cells on the upper side were wiped, and invaded cells on the lower side were stained with 1% crystal violet (BioTime Inc., Alameda, CA, USA) and imaged and counted under three microscopic fields (light microscope; magnification, ×100).

### Statistical analysis

All statistical analyses were performed using GraphPad Prism version 5.02 software (GraphPad Software, Inc., La Jolla, CA, USA). Differences in LHX2 and miR-124 expression levels between NSCLC tissues (T) and adjacent noncancerous lung tissues(N)were analyzed using a paired t-test (two-tailed), and data are presented as the mean ± standard error. Comparisons between clinicopathological characteristics and expression ratios (T/N) of LHX2 and miR-124 in NSCLC tissues were performed using nonparametric tests (Mann-Whitney U test for 2 groups, Kruskal-Wallis test for ≥3 groups). For cell lines, differences between 2 groups were assessed using an unpaired t-test (two-tailed), and data are presented as the mean ± standard deviation. Correlation between two groups was analyzed using the Pearson\'s correlation test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### LHX2 expression is increased in NSCLC cells and tissues

LHX2 is involved in various types of human cancer, including NSCLC ([@b18-ol-0-0-6607]). To further verify whether LHX2 expression is associated with NSCLC, the present study first examined the expression level of LHX2 in seven NSCLC cell lines. As shown in [Fig. 1A and B](#f1-ol-0-0-6607){ref-type="fig"}, the levels of LHX2 mRNA and protein expression were significantly higher in seven NSCLC cell lines (H226, LTEP-a-2, A549, 95C, H460, 95D and H1299) compared with the control HBE cells. Subsequently, the level of LHX2 mRNA expression was detected in 40 paired NSCLC tissues and adjacent noncancerous lung tissues, and this analysis revealed that LHX2 mRNA expression was significantly higher in NSCLC tissues compared with the paired noncancerous lung tissues ([Fig. 1C](#f1-ol-0-0-6607){ref-type="fig"}). When classified by various clinicopathological characteristics, NSCLC samples did not reveal any difference in the LHX2 mRNA expression level ratio (T/N) ([Table II](#tII-ol-0-0-6607){ref-type="table"}).

### Expression of miR-124 is decreased and negatively associated with the level of LHX2 expression in NSCLC cells and tissues

As presented in [Fig. 1D](#f1-ol-0-0-6607){ref-type="fig"}, the expression of miR-124 was significantly lower in seven NSCLC cell lines (H226, LTEP-a-2, A549, 95C, H460, 95D and H1299) compared with the expression in HBE cells. Furthermore, miR-124 expression level was significantly lower in NSCLC tissues compared with the paired noncancerous lung tissues ([Fig. 1E](#f1-ol-0-0-6607){ref-type="fig"}). No significant difference in miR-124expression ratio (T/N) was revealed between NSCLC samples when classified by various clinicopathological characteristics ([Table II](#tII-ol-0-0-6607){ref-type="table"}). Of note, the ratio of miR-124 expression level (T/N) was inversely associated with LHX2 mRNA expression level (T/N) in 40 paired tissues ([Fig. 1F](#f1-ol-0-0-6607){ref-type="fig"}). The results, analyzed using Pearson\'s correlation test, suggested that there may be a correlation between miR-124 and LHX2 expression levels in NSCLCs.

### miR-124 suppresses LHX2 expression level by targeting LHX2 3′-UTR in NSCLC cells

As shown in [Fig. 2A](#f2-ol-0-0-6607){ref-type="fig"}, a markedly increased expression level of miR-124 was observed in A549 and H1299 cells when transiently transfected with miR-124 mimic. Notably, miR-124 overexpression significantly inhibited LHX2 mRNA and protein expression levels in A549 and H1299 cells ([Fig. 2B](#f2-ol-0-0-6607){ref-type="fig"}), and miR-124 downregulation ([Fig. 2C](#f2-ol-0-0-6607){ref-type="fig"}) markedly promoted LHX2 mRNA and protein expression levels in A549 and H1299 cells ([Fig. 2D](#f2-ol-0-0-6607){ref-type="fig"}), suggesting that miR-124 served an important role in downregulating LHX2 in NSCLC. To further investigate the molecular mechanisms underlying this inhibition effect, the present study first used TargetScanHuman (version 7.0) software, which identified LHX2 3′-UTR to be a putative target of miR-124. Therefore, in order to confirm this, the present study subcloned LHX2 3′-UTR containing the miR-124 binding site (wild-type/mutant) into psiCHECK-2 vectors ([Fig. 2E](#f2-ol-0-0-6607){ref-type="fig"}) and transiently co-transfected the reporter vector with miR-124 mimic into NSCLC cell lines A549 and H1299. The results of the luciferase reporter assay demonstrated that miR-124 significantly inhibited the luciferase activities in NSCLC cells transfected with the LHX2 3′-UTR wild-type plasmids, whereas miR-124 did not suppress the luciferase activities in cells transfected with the mutant vectors ([Fig. 2F](#f2-ol-0-0-6607){ref-type="fig"}). Taken together, the results indicated that miR-124 may directly target the 3′-UTR of LHX2 and thereby reduced the expression level of LHX2.

### miR-124 overexpression or knockdown of LHX2 represses NSCLC cell migration and invasion

Given the observation that miR-124 may attenuate NSCLC metastasis by targeting MYO10 ([@b13-ol-0-0-6607]) and the results of the present study, whether repression of LHX2 expression by miR-124 may inhibit NSCLC cell migration and invasion was subsequently investigated. In support of this hypothesis, the Transwell assay revealed that A549 and H1299 cells overexpressing miR-124 exhibited an impaired ability to migrate and invade ([Fig. 3A and B](#f3-ol-0-0-6607){ref-type="fig"}). Furthermore, A549 and H1299 cells with downregulated miR-124 expression demonstrated increased migratory and invasive abilities ([Fig. 3C and D](#f3-ol-0-0-6607){ref-type="fig"}). Notably, knockdown of LHX2 ([Fig. 4A and B](#f4-ol-0-0-6607){ref-type="fig"}) suppressed migratory and invasive abilities of A549 and H1299 cells ([Fig. 4C and D](#f4-ol-0-0-6607){ref-type="fig"}). Taken together, the results suggested that miR-124 may attenuate NSCLC cell migration and invasion by targeting LHX2.

Discussion
==========

LHX2 serves important roles in multiple biological processes, including embryo development ([@b16-ol-0-0-6607]), cell fate decision, proliferation ([@b21-ol-0-0-6607]) and cell differentiation ([@b22-ol-0-0-6607]). Therefore, aberrant expression of LHX2 may be associated with certain human diseases, including cancer. High levels of LHX2 were expressed in pancreatic ductal adenocarcinoma ([@b23-ol-0-0-6607]). In present study, it was revealed that LHX2 was highly expressed in NSCLC cells and tissues. Although the authors of the present study have previously reported that knockdown of LHX2 attenuated NSCLC cell proliferation ([@b18-ol-0-0-6607]), whether LHX2 expression affects NSCLC cell migration and invasion has not yet been investigated. Kuzmanov *et al* ([@b17-ol-0-0-6607]) reported that LHX2 functioned as a promoter of metastasis in breast cancer cells. In the present study, the findings indicated that knockdown of LHX2 significantly inhibited the aggressive abilities of NSCLC cells.

Subsequently, the present study investigated the miRNA-mediated mechanism underlying LHX2 regulation in NSCLC cell migration and invasion. Considering the idea that miRNAs serve a key role in regulating various gene expression levels at the post-transcriptional level ([@b24-ol-0-0-6607]) and *in silico* prediction which identified the 3′-UTR of LHX2 transcript to be a putative target of miR-124, the present study performed cell-based and biochemical analyses to confirm this. Firstly, the present study revealed that LHX2 expression level was markedly downregulated and upregulated in NSCLC cells when transiently transfected with miR-124 mimic and miR-124 inhibitor, respectively. Secondly, luciferase reporter assays demonstrated that miR-124 repressed LHX2 expression level by targeting a specific site of the LHX2 3′-UTR. To the best of our knowledge, this is the first evidence that miR-124 targets LHX2 and inhibits its expression in NSCLC cells. In addition, the present study observed that miR-124 overexpression inhibited NSCLC cell migration and invasion, which was consistent with the results from a previous study by Sun *et al* ([@b13-ol-0-0-6607]). The phenotype of miR-124 overexpression was the same as the phenotype of NSCLC cells with knockdown of LHX2, which presented an attenuated aggressive ability, suggesting that miR-124 may inhibit NSCLC cell migration and invasion by targeting LHX2. Of note, miR-124 may also target MYO10 and inhibit NSCLC metastasis ([@b13-ol-0-0-6607]). This is not surprising because single miRNA have been reported to regulate various target genes to exert its function ([@b25-ol-0-0-6607]). In further support of this, miR-124 directly targets ESX/epidermal growth factor receptor or talin 1 to suppress cell invasion in head and neck squamous cell carcinoma ([@b11-ol-0-0-6607]) and prostate cancer ([@b26-ol-0-0-6607]).

Recently, a low level of miR-124 expression was demonstrated to be significantly associated with positive lymph node metastasis and poor prognosis in human cancer, including NSCLC ([@b14-ol-0-0-6607],[@b15-ol-0-0-6607]). The present study observed that miR-124 inhibition increased the migratory and invasive abilities of NSCLC cells, and miR-124 was downregulated in NSCLC tissues. However, due to the limited sample size, the present study failed to reveal the significant association of miR-124 expression level with lymph node metastasis in NSCLC tissues. Furthermore, the results demonstrated that a low expression level of miR-124 was inversely associated with a high level of LHX2 expression in NSCLCs.

In conclusion, the present study provided the first evidence that LHX2 is involved in NSCLC cell migration and invasion, which was regulated at least partially by miR-124.Mechanistically, miR-124 reduced LHX2 expression by directly targeting the LHX2 3′-UTR. The results of the present study suggest that overexpression of miR-124 or silencing of LHX2 may provide a therapeutic strategy for advanced NSCLC.
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![High LHX2 and low miR-124 expression levels in human NSCLC cells and tissues. (A) RT-qPCR analysis of LHX2 mRNA levels in HBE and NSCLC cells. LHX2 mRNA expression levels are presented as a relative index normalized against β-actin. Data is presented as the mean ± standard deviation of three replicates. (B) Western blot analysis of LHX2 protein levels in HBE and NSCLC cells. β-actin was used as the loading control. (C) Difference in relative LHX2 mRNA expression levels between 40 paired tumor tissues and adjacent noncancerous tissues. Data were analyzed using the paired t-test and presented as the mean ± standard error. (D) RT-qPCR analysis of miR-124 expression levels in HBE and NSCLC cells. miR-124 expression levels were expressed as a relative index normalized against U6. (E) Relative miR-124 expression levels in 40 paired tumor tissues and adjacent noncancerous tissues. Difference in miR-124 expression level between tumor tissues and adjacent noncancerous tissues was analyzed by paired t-test. Data are presented as the mean ± standard error. (F) Correlation between miR-124 and LHX2 mRNA expression levels in 40 paired NSCLC tissues. × and y axes represent the log~10~ transformed fold change of tumor/noncancerous tissue mRNA expression ratios of miR-124 and LHX2, respectively. \*P\<0.05; \*\*P\<0.01; \*\*\*P\<0.001. NSCLC, non-small cell lung cancer; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; LHX2, LIM-homeobox domain 2; miR, microRNA; HBE, human bronchial epithelial; T, tumor; N, noncancerous lung tissues.](ol-14-03-3429-g00){#f1-ol-0-0-6607}

![miR-124 reduces LHX2 expression level in NSCLC cells by targeting LHX2 3′-UTR. (A) RT-qPCR analysis of miR-124 expression levels in A549 and H1299 cells transfected with miR-124 mimics or miR-NC for 48 h. Scrambled sequences were used as miR-NC, and U6 was used as an internal control. (B) LHX2 mRNA and protein expression levels in A549 and H1299 cells transfected with miR-124 mimics or miR-NC for 48 h. (C) miR-124 expression levels in A549 and H1299 cells transfected with miR-124 inhibitor (anti-miR-124) or negative control (anti-miR-NC). (D) LHX2 mRNA and protein expression levels in A549 and H1299 cells transfected with anti-miR-124 or anti-miR-NC. (E) Schematic diagram showing the cloning of one predicted miR-124 binding site of LHX2 3′-UTR in psiCHECK-2 luciferase constructs. (F) Relative luciferase activities of the wild-type or mutant LHX2 3′-UTR reporter gene in A549 and H1299 cells transfected with miR-124 mimics or miR-NC. Relative *Renilla* luciferase activity was determined by normalization to firefly luciferase activity. Data is presented as the mean ± standard deviation of three replicates. \*P\<0.05; \*\*P\<0.01; \*\*\*P\<0.001. 3′-UTR, 3′ untranslated region; miR, microRNA; LHX2, LIM-homeobox domain 2; NSCLC, non-small cell lung cancer; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; NC, negative control.](ol-14-03-3429-g01){#f2-ol-0-0-6607}

![miR-124 suppresses migration and invasion of NSCLC cells. (A) Transwell assays of A549 cells and H1299 cells transfected with miR-124 or miR-NC. Following transfection with miR-124 or miR-NC for 24 h, A549 and H1299 cells were allowed to invade through an 8 µM pore in Transwell chambers. Migrated and invaded cells were stained and counted in ≥3 microscopic fields (magnification, ×100). (B) Bar charts presenting the number of miR-124 mimics or miR-NC-transfected cells that have undergone migration or invasion. Data are presented as the mean ± standard deviation of three independent fields. (C) Transwell assays for A549 cells and H1299 cells transfected with anti-miR-124 or anti-miR-NC. (D) Bar charts presenting the number of anti-miR-124 or anti-miR-NC-transfected cells that have undergone migration or invasion. \*\*\*P\<0.001. miR, microRNA; NSCLC, non-small cell lung cancer; NC, negative control.](ol-14-03-3429-g02){#f3-ol-0-0-6607}

![Knockdown of LHX2 inhibits migration and invasion of NSCLC cells. The levels of LHX2 mRNA and protein in (A) A549 cells and (B) H1299 cells transfected with si-LHX2-1, si-LHX2-2or si-NCfor 48 h. Transwell assays for (C) A549 and (D) H1299 cells transfected with si-LHX2-1, si-LHX2-2 or si-NC. LHX2-silenced A549 and H1299 cells were allowed to migrate and invade through an 8 µM pore in Transwell chambers. Migrated and invaded cells were stained and counted in ≥3 microscopic fields (magnification, ×100). Data in the bar charts are presented as the mean ± standard deviation of three independent fields.\*\*\*P\<0.001. si, short interfering; LHX2, LIM-homeobox domain 2; NSCLC, non-small cell lung cancer; NC negative control.](ol-14-03-3429-g03){#f4-ol-0-0-6607}

###### 

Primers for reverse transcription or amplification of miR-124 and LHX2 mRNA.

  Primer               Sequence (5′-3′)
  -------------------- ----------------------------------------------------
  RT                   
    U6                 CGAGCACAGAATCGCTTCACGAATTTGCGTGTCAT
    miR-124            GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGGCATT
  qPCR                 
    U6, forward        CGAGCACAGAATCGCTTCA
    U6, reverse        CTCGCTTCGGCAGCACATAT
    miR-124, forward   GTGCAGGGTCCGAGGTATT
    miR-124, reverse   GCTAATAAGGCACGCGGTG
    β-actin, forward   CACAGAGCCTCGCCTTTGCC;
    β-actin, reverse   ACCCATGCCCACCATCACG
    LHX2, forward      TTCCAGAACGCCCGAGCCAA
    LHX2, reverse      GGGGCTAGTCAAGTCTGTC

miR, microRNA; LHX2, LIM-homeobox domain 2; RT-PCR, reverse transcription polymerase chain reaction; qPCR, quantitative PCR.

###### 

Comparison of various clinicopathological parameters with LHX2 mRNA and miR-124 expression in 40 NSCLC samples.

                                                              Ratio of expression (T/N)   
  ------------------------------------------------------ ---- --------------------------- -----------
  Age                                                                                     
    ≤65                                                  18   20.61±7.69                  0.73±0.19
    \>65                                                 22   7.41±2.55                   0.68±0.22
  ^[a](#tfn3-ol-0-0-6607){ref-type="table-fn"}^P-value        0.086                       0.864
  Sex                                                                                     
    Male                                                 28   13.56±4.96                  0.67±0.20
    Female                                               12   12.80±5.67                  6.03±5.23
  ^[a](#tfn3-ol-0-0-6607){ref-type="table-fn"}^P-value        0.929                       0.144
  Smoking status                                                                          
    No                                                   20   12.13±3.91                  3.82±3.15
    Yes                                                  20   14.54±6.68                  0.73±0.27
  ^[a](#tfn3-ol-0-0-6607){ref-type="table-fn"}^P-value        0.892                       0.298
  Lymph node metastasis                                                                   
    No                                                   20   14.13±6.67                  3.76±3.15
    Yes                                                  20   12.54±3.95                  0.79±0.27
  ^[a](#tfn3-ol-0-0-6607){ref-type="table-fn"}^P-value        0.267                       0.543
  Histology                                                                               
    Adenocarcinoma                                       23   10.16±3.71                  3.38±2.74
    Squamous cell carcinoma                              14   18.37±8.82                  0.89±0.37
    Others                                               3    14.17±13.59                 0.29±0.12
  ^[b](#tfn4-ol-0-0-6607){ref-type="table-fn"}^P-value        0.205                       0.669

Data are presented as the mean ± standard error.

Mann-Whitney *U* test between two groups.

Kruskall-Wallis test for ≥3 groups. NSCLC, non-small cell lung cancer; T, NSCLC tissues; N, paired noncancerous lung tissues; miR, microRNA; LHX2, LIM-homeobox domain 2.
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